APA (7th ed.) Citation

Greenberg, H. E., Gottesdiener, K., Huntington, M., Wong, P., Larson, P., Wildonger, L., . . . Waldman, S. A. (2000). A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers. Journal of clinical pharmacology, 40(12 Pt 2), 1509. https://doi.org/10.1177/009127000004001224

Chicago Style (17th ed.) Citation

Greenberg, H E., K. Gottesdiener, M. Huntington, P. Wong, P. Larson, L. Wildonger, L. Gillen, E. Dorval, and S A. Waldman. "A New Cyclooxygenase-2 Inhibitor, Rofecoxib (VIOXX), Did Not Alter the Antiplatelet Effects of Low-dose Aspirin in Healthy Volunteers." Journal of Clinical Pharmacology 40, no. 12 Pt 2 (2000): 1509. https://doi.org/10.1177/009127000004001224.

MLA (9th ed.) Citation

Greenberg, H E., et al. "A New Cyclooxygenase-2 Inhibitor, Rofecoxib (VIOXX), Did Not Alter the Antiplatelet Effects of Low-dose Aspirin in Healthy Volunteers." Journal of Clinical Pharmacology, vol. 40, no. 12 Pt 2, 2000, p. 1509, https://doi.org/10.1177/009127000004001224.